Neurology

Your Article Summary

See Latest Articles

Relationship between ALS and the degree of cognitive impairment, markers of neurodegeneration and predictors for poor outcome. A prospective study
European Journal of Neurology, 07/02/09

Rusina R et al. – A prospective study shows age, disease severity and CSF beta-amyloid levels together as a risk factor suggesting shorter survival times. Dementia is relatively frequent in amyotrophic lateral sclerosis (ALS) and may be a consequence of either frontotemporal lobar degeneration (FTLD) or result from co-existing Alzheimer disease.

• Prospective study of 67 pts, 42 women, and 25 men, with clinically defined ALS
• Assessment of disease severity
• SPECT, lumbar puncture with determination of tau, hyperphosporylated tau (p-tau) and beta-amyloid and detailed neuropsychological assessment by standardized test battery
• Detailed neuropathologic evaluation for deceased pts

• Mean survival duration: 26.8 mo
• Delay between first signs and confirmation of diagnosis: 12.75 mo
• Cognitive impairment did not affect disease evolution
• No correlation between neuropsychological and SPECT findings
• Higher age at onset, more pronounced handicap and elevated beta-amyloid in CSF associated with shorter survival times
• In brain tissue from 9 of the deceased patients with ALS and dementia, all showed signs of comorbidity, 6 had FTLD hallmarks, and 3 showed Alzheimer disease pathology
• Brain tissues from 11 deceased ALS pts who did not show signs of dementia had only changes compatible with diagnosis of motor neuron disease

Today in Demyelinating Disorders...keeping you current

Receive free subspecialty "5-minute updates" via email

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial : The Lancet
The Lancet - Early Online Publication, 10/08/09

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial
The Lancet, 11/03/09

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial
The Lancet Neurology, 10/16/09

See All of Demyelinating Disorders